Journal of Chiropractic Medicine
Volume 9, Issue 1 , Pages 11-16 , March 2010

Abdominal and back pain in a 65-year-old patient with metastatic prostate cancer

  • Theodore L. Johnson Jr, DC

      Affiliations

    • Corresponding Author InformationAssistant Dean for Chiropractic Medicine, National University of Health Sciences, 200 East Roosevelt Rd, Lombard, IL 60148. Tel.: +1 630 889 6559; fax: +1 630 889 6559.

Received 20 July 2009 ,Revised 22 September 2009 ,Accepted 5 October 2009.

References 

  1. American Cancer Society. Cancer facts & figures 2009. Atlanta, GA: Elsevier; 2009;Available at http://www.cancer.org/downloads/STT/500809web.pdfAccessed June 28, 2009
  2. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59:264–273
  3. Lim LS, Sherin K, ACPM Prevention Practice Committee . Screening for prostate cancer in U.S. men: ACPM position statement on preventive practice. Am J Prev Med. 2008;34(2):164–170
  4. U.S. Preventive Services Task Force . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191
  5. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008;58:161–179
  6. Grönberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–864
  7. Strief DM. An overview of prostate cancer: diagnosis and treatment. Medsurg Nurs. 2008;17(4):258–263
  8. Lishchyna N, Henderson S. Acute onset-low back pain and hip pain secondary to metastatic prostate cancer: a case report. J Can Chiropr Assoc. 2004;48(1):5–12
  9. Hamilton W, Sharp DJ, Peters TJ, Round AP. Clinical features of prostate cancer before diagnosis: a population-based, case-control study. Br J Gen Pract. 2006;56:756–762
  10. Sarma AV, McLaughlin JC, Wallner LP, et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol. 2006;176:1108–1113
  11. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007;176(13):1853–1858
  12. Rosser CJ. Prostate cancer—to screen, or not to screen, is that the question?. BMC Urol. 2008;8:20
  13. Andriole GL, Crawford ED, Grubb RL, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  14. Fritz FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  15. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009;57:24–30
  16. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317–322
  17. Canby-Hagino E, Hernandez J, Brand TC, et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urol. 2007;70:748–752
  18. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  19. Quinlan MR, Teahan S, Mulvin D, Quinlan DM. Is digital rectal examination still necessary in the early detection of prostate cancer?. Ir J Med Sci. 2007;176:161–163
  20. Galic J, Karner I, Cenan L, et al. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer. Coll Antropol. 2003;27(Suppl 1):61–66
  21. Fowler JE, Bigler SA, Farabaugh PB. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer. 2002;94:1661–1667
  22. LaSpina M, Haas GP. Update on the diagnosis and management of prostate cancer. Can J Urol. 2008;15(Suppl 1):3–13
  23. Wiebe E, Rodrigues G, Lock M, D'Souza D, Stitt L. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml. Can J Urol. 2008;15(3):4078–4083
  24. Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required?. J Urol. 2002;168:1990–1993

PII: S1556-3707(10)00005-2

doi: 10.1016/j.jcm.2009.12.004

Journal of Chiropractic Medicine
Volume 9, Issue 1 , Pages 11-16 , March 2010

Article Tools